(Q40517546)

21 September 2017

1 reference

title

Cytokines and clinical gene therapy (English)

1 reference

21 September 2017

0 references

Schmidt-Wolf G

1

1 reference

21 September 2017

Schmidt-Wolf IG

series ordinal

2

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 April 1995

1 reference

European Journal of Immunology

21 September 2017

published in

1 reference

21 September 2017

volume

25

1 reference

21 September 2017

issue

4

1 reference

21 September 2017

page(s)

1137-1140

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

21 September 2017

1 reference

7 January 2021

Gene therapy, concepts, current trials and future directions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Clinical effects and toxicity of interleukin-2 in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Possible myocardial toxicity associated with interleukin-4 therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Human gene therapy comes of age.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Gene therapy gathers speed in Germany

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Experimental and clinical studies of cytokine gene-modified tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

TNF/TIL human gene therapy clinical protocol

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Interleukin 7 induces CD4+ T cell-dependent tumor rejection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250445

7 January 2021

Identifiers

DOI

10.1002/EJI.1830250445

1 reference

21 September 2017

1 reference